---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-007072"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:52:02.039363+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023

## Summary
- Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.
- SC291 Phase 1 ARDENT trial enrolling; granted Fast Track for r/r large B-cell lymphoma and CLL.
- Plan to file INDs for SC262 and SG299 in H2 2023; SC451 IND in 2024.
- Appointed Dr. Doug Williams as President of R&D and Dr. Gary Meininger as CMO.
- Net loss $82.1M ($0.43/share) vs $31.4M ($0.17) prior year; R&D expense $67.2M down 7.6%.

## SEC filing metadata
- accession: 0001564590-23-007072
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/0001564590-23-007072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/sana-8k_20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-007072
- JSON: https://secwatch.observer/filing/0001564590-23-007072.json
- Plain text: https://secwatch.observer/filing/0001564590-23-007072.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2023.
  - Period: the quarter and year ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/0001564590-23-007072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.